HEPION PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
HEPION PHARMACEUTICALS, INC. (HEPA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-15.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2021-11-15
- 2021-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month 0.00%.
- 2020-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month |
|---|---|
| 2021-09-30 | 0.00% 10-Q · filed 2021-11-15 |
| 2020-09-30 | 0.00% 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |